Loading...
Market
How many patients will report significant vision improvement in the ATSN-101 trial by March 31, 2025?
2
Resolution / Starting Odds
0-10 patients • 25%
11-20 patients • 25%
21-30 patients • 25%
More than 30 patients • 25%
Clinical trial reports, Atsena Therapeutics press releases
Story
AAV Gene Therapy Shows Promise for LCA1 Caused by GUCY2D Mutations
Sep 10, 2024, 07:31 AM
Recent advancements in AAV gene therapy have shown promising results for patients with Leber congenital amaurosis 1 (LCA1), a rare inherited eye disorder caused by mutations in the GUCY2D gene. AAV gene therapy has demonstrated dramatic improvements in vision for affected patients, with benefits sustained for over a year. The safety and efficacy of this therapy, specifically ATSN-101, were evaluated in a phase 1/2, multicenter, open-label, unilateral dose escalation study. Atsena Therapeutics is at the forefront of this research, highlighting the potential of gene therapy in treating inherited blindness.
View original story
Similar markets
0-5 patients • 25%
6-10 patients • 25%
11-15 patients • 25%
More than 15 patients • 25%
0-25% • 25%
26-50% • 25%
51-75% • 25%
76-100% • 25%
Below 80% • 25%
80% to 85% • 25%
85% to 90% • 25%
Above 90% • 25%
Less than 50% • 25%
50% - 60% • 25%
60% - 70% • 25%
More than 70% • 25%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Yes • 50%
No • 50%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Less than 50% efficacy • 25%
50-69% efficacy • 25%
70-89% efficacy • 25%
90% or higher efficacy • 25%
Europe • 25%
Asia • 25%
South America • 25%
No expansion • 25%
Phase 3 trial initiation • 25%
FDA breakthrough therapy designation • 25%
Partnership with a major pharma • 25%
Other milestone • 25%
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%